4. Artivion Inc. (NYSE:AORT)
Artivion, Inc. (NYSE: AORT) ranks No. 4 as a diversified cardiovascular and aortic-disease company offering surgical adhesives, heart valves, aortic stent grafts, vascular grafts, and implantable human tissues. These products serve complex procedures where physician trust, clinical evidence, reliability, and regulatory approval can create strong barriers to entry.
Second-quarter 2026 revenue increased 11% to $125.8 million from $113 million in the previous-year period, or approximately 9% on a constant-currency basis. Artivion, Inc. (NYSE: AORT) recorded a GAAP net loss of $13.5 million, equal to $0.28 per diluted share, but produced non-GAAP net income of $6.3 million, or $0.13 per diluted share.
The company offers greater product and geographic diversification than many small-cap medical businesses, but investors must closely monitor debt, regulatory timing, foreign-exchange exposure, acquisition expenses, and the gap between GAAP and adjusted profitability. Artivion, Inc. (NYSE: AORT) remains an appealing growth-at-a-reasonable-valuation candidate if management can convert continued revenue expansion into sustainable earnings and cash flow.
